Jaguar Health's Posts Crofelemer Data For Chemo-Induced Diarrhea In Breast Cancer Patients

Jaguar Health Inc JAGX announced the topline results of the investigator-initiated Phase 2 HALT-D trial evaluating crofelemer to prevent chemotherapy-induced diarrhea (CID). The trial included HER2-positive breast cancer patients being treated with trastuzumab, pertuzumab, and a taxane.

  • The study included 51 breast cancer patients randomly assigned to either crofelemer or control standard of care with no prophylactic antidiarrheal medications. 
  • Findings showed that the primary endpoint, the incidence of having diarrhea for two or more days, was not statistically different for the two groups since about 70% of patients had this outcome regardless of the cycle or CID treatment group.
  • The crofelemer group demonstrated better outcomes compared to the control group for several key secondary endpoints.
  • A lower incidence of grade 2 or higher-grade diarrhea for the crofelemer group was seen than the control group during cycle 2 based on patient outcomes and investigator assessments - (9.0% vs. 33.3%) and (9.5% vs. 41.1%), respectively.
  • Based on patient-reported outcomes, no patients in the crofelemer group experienced grade 3 or grade 4 diarrhea during cycle 2 compared to 17.6% of patients in the control group.
  • Price Action: JAGX shares are up 3.10% at $1.50 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralbreast cancerBriefsPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!